Generated: May 25, 2017
|Abstract:||A method for treating or preventing a Pneumocystis carinii infection in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof.|
|Inventor(s):||Latter; Victoria S. (Beckenham, GB2), Gutteridge; Winston E. (Beckenham, GB2), Hudson; Alan T. (Beckenham, GB2)|
|Assignee:||Burroughs Wellcome Co. (Research Triangle Park, NC)|
|Filing Date:||Aug 15, 1989|
|Claims:||1. A method of treating malaria in a mammal comprising administering to said mammal an effective antimalarial amount of a compound 2-[trans-4-(4-chlorophenyl)cyclohexyl]-1,3,4triacetoxynaphthalene. |
2. A pharmaceutical formulation in a form for nasal administration or pulmonary administration comprising an effective antimalaria amount of the compound 2-[trans-4-(4-chlorophenyl)cyclohexyl]-1,3,4triacetoxynaphthalene and a pharmaceutically acceptable carrier therefor.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.